Patents Assigned to Glenmark Pharmaceuticals S.A.
-
Publication number: 20150343058Abstract: A pharmaceutical formulation is described comprising a therapeutically effective amount of an antibody, an acetate buffer, a lyoprotectant, a bulking agent and a surfactant.Type: ApplicationFiled: December 18, 2013Publication date: December 3, 2015Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Jonathan André ALBANESE, Roberto Pier-Lorenzo GIOVANNINI, Kevin Niall O'MAHONY
-
Patent number: 9186360Abstract: The present patent application relates to treatment of a respiratory disorder using TRPA1 antagonists. Particularly, the present patent application relates to treatment of a respiratory disorder using a TRPA1 antagonist, wherein the TRPA1 antagonist is administered by inhalation route to a subject in need thereof.Type: GrantFiled: June 13, 2012Date of Patent: November 17, 2015Assignee: GLENMARK PHARMACEUTICALS S.A.Inventors: Neelima Khairatkar-Joshi, Abhay Kulkarni, Indranil Mukhopadhyay, Vidya Ganapati Kattige, Vikram Mansingh Bhosale, Dinesh Pradeep Wale, Abraham Thomas, Sukeerthi Kumar, Sachin Sundarlal Chaudhari
-
Publication number: 20150239991Abstract: The present invention describes novel hetero-dimeric immunoglobulinvariants or fragments thereof, which have reduced or eliminated binding to Protein A, Protein G or both Protein A and Protein G. Also encompassed in the present invention are methods for the selective purification of hetero-dimeric immunoglobulins or fragments thereof using Protein A and Protein G.Type: ApplicationFiled: September 25, 2013Publication date: August 27, 2015Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Stanislas Blein, Fabrizio Comper, Romain Ollier, Paul Wassmann
-
Patent number: 9096545Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.Type: GrantFiled: June 10, 2013Date of Patent: August 4, 2015Assignee: GLENMARK PHARMACEUTICALS S.A.Inventors: Laxmikant Atmaram Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
-
Patent number: 9073955Abstract: The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.Type: GrantFiled: October 21, 2013Date of Patent: July 7, 2015Assignee: GLENMARK PHARMACEUTICALS, S.A.Inventors: Sukeerthi Kumar, Abraham Thomas, Sachin Sundarlal Chaudhari, Bipin Parsottam Kansagra, Venkata Ramana Yemireddy, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay, Girish Gudi
-
Publication number: 20150111038Abstract: The present disclosure is directed to salts of N-{4-[2,4-difluoro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}dimethyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-5-yl)acetamide and process for the preparation thereof (formula II).Type: ApplicationFiled: June 8, 2013Publication date: April 23, 2015Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Suresh Mahadev Kadam, Abraham Thomas, Sukumar Sinha, Sukeerthi Kumar, Bipin Parsottam Kansagra, Sachin Gavhane, Sandeep Bandu Khandagale, Shailesh Pawase, Jayant Prakashrao Patil, Shailendra Bhadane, Bhavna Mishra, Rajesh Dwivedi
-
Patent number: 9006257Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.Type: GrantFiled: February 7, 2013Date of Patent: April 14, 2015Assignee: Glenmark Pharmaceuticals S.A.Inventors: Laxmikant Atmaram Gharat, Abhisek Banerjee, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
-
Patent number: 9000159Abstract: The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.Type: GrantFiled: November 14, 2013Date of Patent: April 7, 2015Assignee: Glenmark Pharmaceuticals S.A.Inventors: Sachin Sundarlal Chaudhari, Sukeerthi Kumar, Abraham Thomas, Nisha Parag Patil, Ashok Bhausaheb Kadam, Vishal Govindrao Deshmukh, Sachin Vasantrao Dhone, Rajendra Prakash Chikhale, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay
-
Publication number: 20150087646Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.Type: ApplicationFiled: June 10, 2013Publication date: March 26, 2015Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Laxmikant Atmaram Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
-
Patent number: 8987278Abstract: The present invention is related to novel thienopyrimidinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.Type: GrantFiled: June 25, 2013Date of Patent: March 24, 2015Assignee: Glenmark Pharmaceuticals S.A.Inventors: Sukeerthi Kumar, Abraham Thomas, Nayan Taterao Waghmare, Sanjay Margal, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay
-
Publication number: 20140341892Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.Type: ApplicationFiled: May 19, 2014Publication date: November 20, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Elias LAZARIDES, Catherine Woods, Mark Bernard
-
Patent number: 8889862Abstract: The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.Type: GrantFiled: October 21, 2013Date of Patent: November 18, 2014Assignee: Glenmark Pharmaceuticals, S.A.Inventors: Sukeerthi Kumar, Abraham Thomas, Sachin Sundarlal Chaudhari, Bipin Parsottam Kansagra, Venkata Ramana Yemireddy, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay, Girish Gudi
-
Publication number: 20140308271Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.Type: ApplicationFiled: January 2, 2014Publication date: October 16, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: ANTOINE ATTINGER, JONATHAN ALBERT BACK, STANISLAS BLEIN, RAMI LISSILAA, DARKO SKEGRO
-
Publication number: 20140294824Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.Type: ApplicationFiled: March 21, 2014Publication date: October 2, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Antoine ATTINGER, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
-
Publication number: 20140286934Abstract: The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 29; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 31 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 32.Type: ApplicationFiled: January 30, 2014Publication date: September 25, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Stanislas BLEIN, Darko Skegro, Christophe Debonneville, Martin Bertschinger
-
Publication number: 20140187753Abstract: The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.Type: ApplicationFiled: January 29, 2014Publication date: July 3, 2014Applicant: Glenmark Pharmaceuticals S.A.Inventors: Stanislas Blein, Darko Skegro, Paul Wassmann
-
Patent number: 8759009Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.Type: GrantFiled: August 17, 2010Date of Patent: June 24, 2014Assignee: Glenmark Pharmaceuticals S.A.Inventors: Elias Lazarides, Catherine Mary Woods, Mark Bernard
-
Patent number: 8748585Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.Type: GrantFiled: July 10, 2012Date of Patent: June 10, 2014Assignee: Glenmark Pharmaceuticals S.A.Inventors: Antoine Attinger, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
-
Publication number: 20140148423Abstract: The present patent application relates to a pharmaceutical composition comprising a transient receptor potential ankyrin-1 receptor (“TRPA1”) antagonist and a glucocorticoid.Type: ApplicationFiled: July 23, 2012Publication date: May 29, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Neelima Khairatakar-Joshi, Abhay Kulkarni, Dinesh Pradeep Wale, Anil Hari Kadam, Vikram Bhosale
-
Publication number: 20140128603Abstract: The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.Type: ApplicationFiled: November 14, 2013Publication date: May 8, 2014Applicant: Glenmark Pharmaceuticals, S.A.Inventors: Sachin Sundarlal Chaudhari, Sukeerthi Kumar, Abraham Thomas, Nisha Parag Patil, Ashok Bhausaheb Kadam, Vishal Govindrao Deshmukh, Sachin Vasantrao Dhone, Rajendra Prakash Chikhale, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay